Christina T Mora-Mangano, MD
Anesthesiology · Stanford
- Medicare standing
- 4 flags on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare cancelled their billing
- Medicare does not list them as allowed to order and refer
- California licence: Revoked
- 1 Medical Board action on record
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Mora-Mangano’s office at (650) 723-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence G81274 · Revoked
Licence status: Revoked · since 1995 · Umdnj Robert Wood Johnson Medical School.
License has been revoked as a result of disciplinary action rendered by the Board. No practice is permitted.
Public record actions
| 2025-04-01 | Board disciplineDiscipline | Revoked. · 8002021083856 |
Drugs they prescribed that Part D paid
$3,914
Pharmacies billed $3,914 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 26) in 2024. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
11 generic and 15 brand-name prescriptions · $3,914 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 26 | None | 0% (0) | 58% | $3,914 |
| 2023 | 16 | None | 0% (0) | None | $721 |
| 2022 | 12 | None | 0% (0) | None | $568 |
| 2021 | 20 | None | 0% (0) | None | $1,565 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Grifols Therapeutics LLC · A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiac Surgery With Cardiopulmonary Bypass · 2019 | Their institution | $37,934 |
Professional record
- NPI
- 1972520674
- Licence
- CA G81274California G81274: Revoked
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G812740
- Taxonomy
- Federal specialty code 207L00000X (207L00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-07-17
- NPI last updated
- 2009-11-24
This is when the NPI record was last certified, not a medical board exam.